Jun. 8 at 3:13 PM
Because shorts are about to get crushed. Taletrectrinib may be the best-in-class ROS-1 inhibitor and has a likely approval in 15 days!!
$NUVB . At this point: I will gladly take the alternate viewpoint and continue adding shares of Nuvation on any dip as I have been over the past few weeks.
I think I’ll stop with the daily posts about Tonix’s likely approval for Tonmya (fibromyaglia) on a daily count given they’re 16 days away although that has more upside potential than either Nuvation or Nuvalent
$NUVL
Fellow
$TNXP bulls - check out Nuvation (ROS1+ NSCLC) or Kalvista
$KALV (a rare disease called HAE) for some likely June approvals.
I’m not invested in Kalvista (yet!) but am excited for those patients to have an oral option.
GLL! 👍 ☘️ 🚀
Patients are waiting. ⏰
~Jeff
15 Days Away for Nuvation!
